← All trials
NCT03424044
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 29, 2018
- Primary completion
- Feb 28, 2019
- Completion date
- Jun 30, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 19
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Oregon Health and Science UniversityLead sponsor
- Oregon Health and Science UniversityReponsible party - principal investigator
- Oregon Health and Science UniversityOverall official - principal investigator
- Xeris PharmaceuticalsCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.